Pfizer enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1031034951121,823
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.52.52.52.52.5
−100−100−493−110−1,820
4,2054,2054,2203,5983,210
0.1%0.1%0.1%0.1%0.1%
Reference items — trailing FY values
2,5702,5202,2812,1932,425
942904740635809
884846679573703
—968660257—
942942632238—
—940629234—
—25.228.218.9—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PFIZER₹3,734.40

Pfizer Ltd.

· Pharma & Health
₹ CrorePeersGLAXOABBOTINDIAPOLYMEDONESOURCERAINBOWKIMSJUBLPHARMAVIJAYA
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
- Cash, Equiv & ST Investments1,822.9112.0495.1102.7102.7
+ Total Debt2.52.52.52.52.5
Net Debt (memo)-1,820.4-109.5-492.6-100.2-100.2
Total Capital3,209.83,598.04,219.94,205.44,205.4
Total Debt/Total Capital0.080.070.060.060.06
Reference Items — Trailing FY Values
Sales2,424.82,193.22,281.42,519.72,569.8
EBITDA808.9635.3740.2904.1941.6
EBIT703.4573.0679.4846.4884.1
Operating Cash Flow—256.8659.8967.6—
Free Cash Flow—237.9631.6942.3942.3
FCFF (free cash flow to the firm)—234.1629.5940.0—
Capital Expenditure—18.928.225.2—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.